drugset / Trial / NCT01401517

Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC

NCT01401517

Phase 2 Completed 55 enrolled TheraVasc Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Sodium nitrite has been demonstrated to promote new blood vessel growth, speed up wound healing and prevent tissue necrosis in animals. Since patients with PAD experience many of these problems, this study will seek to determine whether this drug, when given orally, could provide the same benefits to patients with PAD.

Timeline

Start
2011-07
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sodium Nitrite Small molecule 40 mg Oral
Subject Sodium Nitrite Small molecule 80 mg Oral